Olympus Announces Exclusive U.S. Co-Marketing Agreement with Bracco Diagnostics, Inc.
Retrieved on:
Thursday, May 19, 2022
Storm, Physician, Laparoscopy, EUS, Olympus, Fair Employment Practice Committee, Porter Adventist Hospital, Nausea, Hypersensitivity, Radiation, Sulfur hexafluoride, DDW, Multimedia, Patient, Quality of life, Constance J. Chang-Hasnain, Liver, Microparticle, Bleeding, Endoscopy, Bracco (company), Awareness, Liver disease, Center, Safety, Pathology, Headache, GI, Diagnosis, PMID, Microbubble, Perforation, Medical device, Medical imaging, Pharmaceutical industry, Medicine
CENTER VALLEY, Pa., May 19, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today a strategic co-marketing agreement with Monroe Township, N.J.-based Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business. Through this agreement, Olympus and Bracco will work together to raise awareness of the role of endoscopic ultrasound (EUS) with contrast in the characterization of focal liver lesions. The contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) technology will open pathways for more innovative and timely diagnosis and treatment of liver disease.
Key Points:
- Through this agreement, Olympus and Bracco will work together to raise awareness of the role of endoscopic ultrasound (EUS) with contrast in the characterization of focal liver lesions.
- More detailed visualization during minimally invasive procedures can provide more information to physicians for use in diagnosis.
- Per the terms of the agreement, Olympus will co-market the Lumason ultrasound enhancing agent with Bracco Diagnostics, Inc. Risks associated with the use of Lumason include headache and nausea.
- "We gain from this agreement an additional pathway to discuss with physicians the importance of better specificity in diagnosing liver malignancies.